touchEXPERT OPINIONS Personalized treatment of RET-altered thyroid cancers: What is the value of biomarker testing and targeted therapies?
Leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers
Prof. Maria Cabanillas outlines the different types of thyroid cancer, their epidemiology and the range of multikinase and targeted kinase inhibitor therapies available for the management of thyroid cancer.1/3 Next Interview
Dr Vivek Subbiah explains the concept of RET alterations in thyroid cancer, the methods available to detect these biomarkers, and how detecting RET alterations can influence treatment decision making and patient outcomes.2/3 Next Interview
Dr Lori Wirth reviews the latest efficacy and safety data on targeted tyrosine kinase inhibitor therapies for patients with RET-altered thyroid cancers, and their implications for clinical practice.3/3 Take CE/CME Test
Learning Objectives & Overview
In this activity, thyroid cancer specialists share their perspectives on key aspects of RET-altered thyroid cancers, including the epidemiology of the disease, the importance of biomarker testing and the latest data on targeted therapies for patients with RET alterations.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of oncologists, oncology surgeons, endocrinologists, nuclear medicine physicians, radiologists, pathologists and oncology nurse specialists involved in the management of patients with thyroid cancer.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Prof. Maria Cabanillas discloses Advisory board or panel fees from Bayer, Eli Lilly and Exelixis. Consultancy fees from Bayer and Eli Lilly. Grant research/support from Genentech and Merck.
Dr Vivek Subbiah discloses Advisory board or panel fees from Daiichi Sankyo, Eli Lilly/LOXO Oncology, Helsinn, Incyte, Medimmune, Novartis, QED Pharma, Relay Therapeutics, Roche and Signant Health. Consultancy fees from Daiichi Sankyo, Eli Lilly/LOXO Oncology, Helsinn, Incyte, Medimmune, Novartis, QED Pharma, Relay Therapeutics, Roche and Signant Health. Grant research/support from Abbvie, Agensys, Alfasigma, Altum, Amgen, Bayer, Berghealth, Blueprint Medicines Corporation, Boston Biomedical, Boston Pharmaceuticals, Celgene, D3, Dragonfly Therapeutics, Eli Lilly/LOXO Oncology, Exelixis, Fujifilm, GlaxoSmithKline, Helsinn Pharmaceuticals, Idera Pharma, Incyte, Inhibrx, Medimmune, Multivir, Nanocarrier, Northwest Biotherapeutics, Novartis, Pfizer, Pharmamar, Roche/Genentech, Takeda, Turning Point Therapeutics and Vegenics. Other financial or material support (royalties, patents, etc.) from Incyte and Pharmamar.
Dr Lori Wirth discloses Advisory board or panel fees from Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Eli Lilly and Exelixis. Consultancy fees from Eisai.
Nurse planner and peer reviewer Alicia Canalejo, APRN, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Sola Neunie has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact email@example.com
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.
This activity is awarded 1.0 ANCC pharmacotherapeutic contact hour.
Date of original release: 16 March 2022. Date credits expire: 16 March 2023.
If you have any questions regarding credit please contact firstname.lastname@example.org
After watching this activity, participants should be better able to:
- Distinguish between different types of thyroid cancers and describe therapies that are appropriate for their management
- Plan a personalized approach to treatment of RET-altered thyroid cancers, including use of biomarker testing and novel targeted therapies
- Evaluate the clinical trial data for novel targeted therapies for RET-altered thyroid cancers and apply it to clinical practice
Register to touchONCOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights